Shareholders Equity: The sum of preferred and common equity items.
ZyVersa Therapeutics, Inc. (ZVSA) had Shareholders Equity of $8.52M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-9.41M |
|
-- |
|
-- |
|
$9.14M |
|
$-9.14M |
|
$-0.27M |
|
$-9.41M |
|
$-9.41M |
|
$-9.41M |
|
$-9.41M |
|
$-9.41M |
|
$-9.41M |
|
$-9.14M |
|
$-9.13M |
|
1.11M |
|
1.11M |
|
$-8.48 |
|
$-8.48 |
|
| Balance Sheet Financials | |
$1.72M |
|
-- |
|
$18.88M |
|
$20.60M |
|
$11.23M |
|
-- |
|
$0.85M |
|
$12.08M |
|
$8.52M |
|
$-10.13M |
|
|
Shareholders Equity |
$8.52M |
2.51M |
|
| Cash Flow Statement Financials | |
$-7.56M |
|
-- |
|
$5.95M |
|
$3.14M |
|
$1.53M |
|
$-1.61M |
|
$0.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.56M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-110.53% |
|
92.91% |
|
-45.70% |
|
-110.53% |
|
$3.40 |
|
$-6.81 |
|
$-6.81 |
|